KROS Jun 2024 75.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 11:03AM EDT
| Previous Close | 24.00 |
| Open | 24.00 |
| Bid | 8.70 |
| Ask | 12.50 |
| Strike | 75.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 24.00 - 24.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3 |
GuruFocus.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
GlobeNewswireKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
Simply Wall St.Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...
© 2024 Yahoo. All rights reserved.